Manufacturer
DUOPHARMA (M) SDN. BHD.
Contents
Prochlorperazine mesylate
Indication
Nausea and vomiting, Mania, Schizophrenia.
Instruction
Administer via IV/IM.
Drug interaction
Enhanced CNS depression with barbiturates and sedatives. Reduced antipsychotic effect with anticholinergics. May reduce the effect of hypoglycaemic agents. Increased risk of arrhythmias with antidepressants. Increased risk of agranulocytosis with carbamazepine. Increased neurotoxicity with lithium. Diminished therapeutic effect of oral anticoagulant. Decreased absorption with antacids.
Malaysia
